Trial Profile
An Open-Label Phase Ib/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, Bcl-2 Inhibitor and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Glasdegib (Primary) ; Ivuxolimab (Primary) ; Utomilumab (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 May 2023 Status changed from active, no longer recruiting to completed.
- 01 Sep 2022 Results assessing the feasibility of a conducting a multi-arm trial to efficiently and simultaneously evaluate novel therapies in acute myeloid leukemia, published in the Leukemia and Lymphoma.
- 25 Jan 2022 Status changed from recruiting to active, no longer recruiting.